SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (20271)6/14/2006 1:47:57 PM
From: Ian@SI  Read Replies (1) | Respond to of 52153
 
With PFE's marketing muscle, I wouldn't be surprised to see it come in at 11.5B to 11.7B; I would be surprised to see it come in at less than 10.5B. Lipitor has grown despite a couple major insurors deleting it from their approved drug lists.



To: Biomaven who wrote (20271)6/14/2006 4:41:36 PM
From: Qualified Opinion  Read Replies (1) | Respond to of 52153
 
Generic Zocor isn't a therapeutic substitution for Lipitor per Pfizer. Physicians would have to be willing to lower their standards and specifically prescribe generic Zocor.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News